Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity

Retina

Volumn 28, Issue 3 SUPPL., 2008, Pages

  Lalwani, Geeta A ^a   Berrocal, Audina M ^a,b   Murray, Timothy G ^a   Buch, Maria ^a   Cardone, Scott ^a   Hess, Ditte ^a   Johnson, Rose A ^a   Puliafito, Carmen A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Alvage treatment; Anti EGF therapy; Etinopathy of prematurity; Evacizumab

Indexed keywords

BEVACIZUMAB;

ARTICLE; CASE REPORT; DRUG INDICATION; ECHOGRAPHY; HUMAN; LASER SURGERY; NEWBORN; OPHTHALMOSCOPY; RETINA DETACHMENT; RETROLENTAL FIBROPLASIA; SALVAGE THERAPY; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; DRUG LABELING; HUMANS; INFANT, NEWBORN; LASER THERAPY; RETINOPATHY OF PREMATURITY; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 43149101294     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181644ad2     Document Type: Article

References (12)